Harrow Health, Inc. (NASDAQ: HROW) owns a portfolio of healthcare businesses, including the nationâs leading ophthalmology pharmaceutical compounding business, ImprimisRx. The company holds large equity positions in Eton Pharmaceuticals, Surface Pharmaceuticals, Melt Pharmaceuticals, Mayfield Pharmaceuticals and Radley Pharmaceuticals, companies founded as subsidiaries of Harrow Health. The Company also owns royalty rights in certain 505(b)(2) drug candidates being developed by Eton, Surface, Melt, Mayfield and Radley. Harrow intends to create, invest in and grow paradigm shifting health care businesses that put patients first. Source
No articles found.
Acceleron is dedicated to the discovery and development of innovative, life-changi...
Acceleron is dedicated to the discovery and dev...
Unlimited Tomorrow is here to change the way we think about artificial limbs. They...
Unlimited Tomorrow is here to change the way we...
Evogene (NASDAQ, TASE: EVGN) is a leading biotechnology company developing novel p...
Evogene (NASDAQ, TASE: EVGN) is a leading biote...
Chimerix is a development-stage biopharmaceutical company dedicated to acceleratin...
Chimerix is a development-stage biopharmaceutic...
Fortress Biotech ("Fortress" or "the Company") is an innovative biopharmaceutical ...
Fortress Biotech ("Fortress" or "the Company") ...
Join the National Investor Network and get the latest information with your interests in mind.